Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
Aliment Pharmacol Ther. 2026 May 12. doi: 10.1111/apt.70711. Online ahead of print.ABSTRACTBACKGROUND: The natural history of steatotic liver disease (SLD)-including major adverse liver outcomes (MALO), major adverse cardiovascular events (MACE), and all-cause mortality-remains inadequately defined

